Key clinical point: The post-diagnostic use of statins and metformin substantially reduced the risk for breast cancer (BC)-specific deaths in patients age ≥ 50 years with primary invasive BC.
Major finding: At a median follow-up of 6.1 years, 2169 BC-specific deaths were reported. Patients who did vs did not use statins (hazard ratio [HR] 0.84; 95% CI 0.75-0.94) and those who used metformin vs other non-metformin antidiabetics (HR 0.70; 95% CI 0.51-0.96) showed 16% and 30% improvement in BC-specific survival rates, respectively.
Study details: Findings are from a nationwide population-based cohort study including 26,190 women with BC, of whom 20%, 29%, and 6% were post-diagnostic users of low-dose aspirin, statins, and metformin, respectively.
Disclosures: This study was funded by the Research Council of Norway. The authors declared no conflicts of interest.
Source: Löfling LL et al. Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: A Norwegian population-based cohort study. Breast Cancer Res. 2023;25:101 (Aug 30). doi: 10.1186/s13058-023-01697-2